

MEDICAL POLICY – 2.02.510

Mobile Cardiac Outpatient Telemetry and Implantable Loop Recorders

BCBSA Ref. Policy: 2.02.08

Effective Date: **Aug. 7, 2026***

Last Revised: Jun. 1, 2026

Replaces: N/A

RELATED MEDICAL POLICIES:

11.01.525 Site of Service Ambulatory Service Center (ASC): Select Surgical Procedures in Adults

*This policy has been revised.


[Click here to view the current policy.](#)

The Site of Service Medical Necessity criteria within this policy DOES NOT apply to Indian Health Services (IHS) facilities.

Please refer to the medical necessity criteria for the procedure only.

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [CODING](#) | [RELATED INFORMATION](#)
[EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

Introduction

Implantable loop recorders (ILRs) and mobile cardiac outpatient telemetry (MCOT) devices are noninvasive technologies used to record and analyze a patient’s heart rhythm during normal daily activities. These systems help detect intermittent or abnormal heart rhythms (arrhythmias) such as atrial fibrillation, bradycardia, or tachycardia, which may not occur during a brief in-office test. MCOT devices provide continuous heart rhythm data to remote monitoring centers, while ILRs offer long-term, automatic rhythm surveillance over months to years. Both technologies allow for extended, outpatient cardiac monitoring providing more comprehensive information than traditional event or Holter monitors. This approach supports accurate diagnoses while allowing patients to remain outside of the hospital setting. This policy describes when ILRs and MCOTs may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Note: There are many cardiac rhythm ambulatory monitoring devices available. Many of these devices are discussed briefly in this policy for informational purposes only. For the purposes of this policy, the scope is only on the mobile cardiac outpatient telemetry (MCOT) and implantable loop recorders (ILRs).

We will review ILRs and MCOT for medical necessity.

The surgical procedure subject to medical necessity review for site of service addressed in this policy is limited to:

- **ILR implantation**

Site of service is defined as the location where the surgical procedure is performed, such as an off campus-outpatient hospital or medical center, an on campus-outpatient hospital or medical center, an ambulatory surgical center, or an inpatient hospital or medical center.

Site of Service for Elective Surgical Procedures	Medical Necessity
Medically necessary sites of service: <ul style="list-style-type: none"> • Ambulatory surgical center 	Certain elective surgical procedures will be covered in the most appropriate, safe, and cost-effective site. This is the preferred medically necessary site of service for certain elective surgical procedures.
<ul style="list-style-type: none"> • Off campus-outpatient hospital/medical center • On campus-outpatient hospital/medical center 	Certain elective surgical procedures will be covered in the most appropriate, safe, and cost-effective site. An elective surgical procedure performed in a hospital outpatient department may be considered medically necessary if there is no access to an ambulatory surgical center due to one of the following criteria:



Site of Service for Elective Surgical Procedures	Medical Necessity
	<ul style="list-style-type: none"> • There is no qualifying ASC within 30 miles that can provide the necessary care due to one of the following: <ul style="list-style-type: none"> ○ There is no geographically accessible ASC that has the necessary equipment to perform the procedure; or ○ There is no geographically accessible ASC available at which the individual’s physician has privileges; or ○ An ASC’s specific guideline prohibits the use of the ASC related to the individual’s health condition or weight, or • Individual is aged 18 or younger, or • The service being performed is in conjunction with an additional service that requires the use of a hospital outpatient department, and the procedures are being performed in the same operative session <p>OR</p> <ul style="list-style-type: none"> • Individual has a clinical condition which puts them at increased risk for complications including any of the following (this list may not be all inclusive): <ul style="list-style-type: none"> ○ Anesthesia Risk <ul style="list-style-type: none"> ▪ ASA classification III or higher (see definition) ▪ Personal history of complication of anesthesia ▪ Documentation of alcohol dependence or history of cocaine use ▪ Prolonged surgery (greater than 3 hours) ○ Cardiovascular Risk <ul style="list-style-type: none"> ▪ Uncompensated chronic heart failure (NYHA class III or IV) ▪ Recent history of myocardial infarction (MI) (less than 3 months) ▪ Poorly controlled, resistant hypertension* ▪ Recent history of cerebrovascular accident (less than 3 months) ▪ Increased risk for cardiac ischemia (drug eluting stent placed less than 1 year or angioplasty less than 90 days) ▪ Symptomatic cardiac arrhythmia despite medication ▪ Significant valvular heart disease



Site of Service for Elective Surgical Procedures	Medical Necessity
	<ul style="list-style-type: none"> ○ Liver Risk <ul style="list-style-type: none"> ▪ Advanced liver disease (MELD Score greater than 8)** ○ Pulmonary Risk <ul style="list-style-type: none"> ▪ Chronic obstructive pulmonary disease (COPD) (FEV1 less than 50%) ▪ Poorly controlled asthma (FEV1 less than 80% despite treatment) ▪ Moderate to severe obstructive sleep apnea (OSA)*** ○ Renal Risk <ul style="list-style-type: none"> ▪ End stage renal disease (on dialysis) ○ Other <ul style="list-style-type: none"> ▪ Morbid obesity (BMI greater than or equal to 50) ▪ Pregnancy ▪ Bleeding disorder (requiring replacement factor, blood products, or special infusion product [DDAVP**** does not meet this criterion]) ▪ Anticipated need for transfusion(s) <p>Note: * 3 or more drugs to control blood pressure ** https://reference.medscape.com/calculator/meld-score-end-stage-liver-disease *** Moderate-AHI greater than or equal to 15 and less than or equal to 30, Severe-AHI greater than or equal to 30 ****DDAVP-Deamino-Delta-D-Arginine Vasopressin (Desmopressin)</p>
<ul style="list-style-type: none"> • Off campus-outpatient hospital/medical center • On campus-outpatient hospital/medical center 	<p>These sites of service are considered not medically necessary for certain elective surgical procedures when the site of service criteria listed above are not met.</p>
<ul style="list-style-type: none"> • Inpatient hospital/medical center 	<p>This site of service is considered not medically necessary for this elective surgical procedure</p>



Procedure	Medical Necessity
<p>Implantable loop recorders (ILRs)</p> <ul style="list-style-type: none"> • Auto-activated • Patient-activated 	<p>The use of either patient-activated or auto-activated ILRs may be considered medically necessary when the following criteria are met:</p> <ul style="list-style-type: none"> • The individual has had a prior non-diagnostic or inconclusive ambulatory cardiac monitoring of at least 14 continuous days <p>AND</p> <ul style="list-style-type: none"> ○ Has recurrent unexplained episodes of presyncope, syncope, palpitations, or dizziness <p>OR</p> <ul style="list-style-type: none"> ○ For evaluation of suspected atrial fibrillation (AF) as a cause of cryptogenic stroke who have had a negative standard workup for AF including 24-hour Holter monitoring
<p>Mobile cardiac outpatient telemetry (MCOT)</p>	<p>The use of MCOT (e.g., CardioNet, LifeStar, ZioAT) may be considered medically necessary when the following criteria are met:</p> <ul style="list-style-type: none"> • An external ambulatory cardiac event monitoring of at least 14 continuous days was performed as non-diagnostic <p>AND</p> <ul style="list-style-type: none"> ○ The individual has symptoms of cardiac arrhythmia, such as recurrent episodes of presyncope, syncope, palpitations, or dizziness, occurring less than once every 48 hours <p>OR</p> <ul style="list-style-type: none"> ○ For evaluation of an individual with suspected AF as a cause of cryptogenic stroke
<ul style="list-style-type: none"> • Implantable loop recorders (ILRs) • Mobile cardiac outpatient telemetry (MCOT) 	<p>Other uses of MCOT and ILRs are considered not medically necessary when the above criteria are not met, or for all other indications including but not limited to monitoring asymptomatic individuals for:</p> <ul style="list-style-type: none"> • Risk factors for arrhythmia • The effectiveness of antiarrhythmic medications • Detection of myocardial ischemia by detecting ST-segment changes



Documentation Requirements

The patient's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:

- Office visit notes that contain the relevant history and physical

For ILRs patient-activated or auto-activated, all of the following should be documented:

- Prior non-diagnostic or inconclusive ambulatory cardiac monitoring* of not less than 14 continuous days

AND

- Unexplained episodes of at least one of the following:
 - Presyncope
 - Syncope
 - Palpitations
 - Dizziness

OR

- Need for evaluation of suspected AF as a cause of cryptogenic stroke

AND

- Completed a negative standard work up for AF including 24-hour Holter monitoring

For MCOT at least one of the following conditions should be documented:

- Previous external ambulatory cardiac event monitoring* for at least 14 continuous days with a non-diagnostic outcome

AND

- Symptomatic cardiac arrhythmia occurring less frequently than once every 48 hours including at least one of the following as a recurrent episodes:
 - Palpitations
 - Dizziness
 - Presyncope
 - Syncope

OR

- Evaluation of suspected atrial fibrillation as a cause of cryptogenic stroke is medically necessary

*(See [Related Information](#) for other examples of ambulatory event monitors)



Coding

Code	Description
CPT	
33285	Insertion, subcutaneous cardiac rhythm monitor, including program
93228	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real-time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional
93229	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional
HCPCS	
C1764	Event recorder, cardiac (implantable)
E0616	Implantable cardiac event recorder with memory, activator, and programmer

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

The available evidence has suggested that long-term monitoring for atrial fibrillation post ablation or after cryptogenic stroke is associated with improved outcomes, but the specific type of monitoring associated with the best outcomes is not well-defined. Trials demonstrating improved outcomes have used either event monitors or implantable monitors. In addition, there are individual considerations that may make one type of monitor preferable over another.



Description

Various devices are available for outpatient cardiac rhythm monitoring. These devices differ in the types of monitoring leads used, the duration and continuity of monitoring, the ability to detect arrhythmias without individual intervention, and the mechanism of delivering the information from individual to clinician. These devices may be used to evaluate symptoms suggestive of arrhythmias (e.g., syncope, palpitations) and may be used to detect atrial fibrillation (AF) in individuals who have undergone cardiac ablation of AF or who have a history of cryptogenic stroke.

Background

Cardiac Arrhythmias

Cardiac monitoring is routinely used in the inpatient setting to detect acute changes in heart rate or rhythm that may need urgent response. For some conditions, a more prolonged period of monitoring in the ambulatory setting is needed to detect heart rate or rhythm abnormalities that may occur infrequently. These cases may include the diagnosis of arrhythmias in individuals with signs and symptoms suggestive of arrhythmias as well as the evaluation of paroxysmal AF.

Cardiac arrhythmias may be suspected because of symptoms suggestive of arrhythmias, including palpitations, dizziness, syncope or presyncope, or because of abnormal heart rate or rhythm noted on exam. A full discussion of the differential diagnosis and evaluation of each of these symptoms is beyond the scope of this policy, but some general principles on the use of ambulatory monitoring are discussed.

Arrhythmias are an important potential cause of syncope or near syncope, which in some cases may be described as dizziness. An electrocardiogram (ECG) is generally indicated whenever there is suspicion of a cardiac cause of syncope. Some arrhythmic causes will be apparent on ECG. However, for individuals in whom an ECG is not diagnostic, longer monitoring may be indicated. The 2009 joint guidelines from the European Society of Cardiology and 3 other medical specialty societies suggested that, in individuals with clinical or ECG features suggesting an arrhythmic syncope, ECG monitoring is indicated; the guidelines also stated that the "duration (and technology) of monitoring should be selected according to the risk and the



predicted recurrence rate of syncope.”¹ Similarly, guidelines from the National Institute for Health and Care Excellence (2023) on the evaluation of transient loss of consciousness, have recommended the use of an ambulatory ECG in individuals with a suspected arrhythmic cause of syncope. The type and duration of monitoring recommended is based on the individual’s history, particularly the frequency of transient loss of consciousness.² The Holter monitor is recommended if transient loss of consciousness occurs several times a week. If the frequency of transient loss of consciousness is every one to two weeks, an external event recorder is recommended if the frequency is less than once every two weeks, an implantable event recorder is recommended.

Similar to syncope, the evaluation and management of palpitations is individual-specific. In cases where the initial history, examination, and ECG findings are suggestive of an arrhythmia, some form of ambulatory ECG monitoring is indicated. A position paper from the European Heart Rhythm Association (2011) indicated that, for individuals with palpitations of unknown origin who have clinical features suggestive of arrhythmia, referral for specialized evaluation with consideration for ambulatory ECG monitoring is indicated.³

Atrial Fibrillation Detection

AF is the most common arrhythmia in adults. It may be asymptomatic or be associated with a broad range of symptoms, including lightheadedness, palpitations, dyspnea, and a variety of more nonspecific symptoms (e.g., fatigue, malaise). It is classified as paroxysmal, persistent, or permanent based on symptom duration. Diagnosed AF may be treated with antiarrhythmic medications with the goal of rate or rhythm control. Other treatments include direct cardioversion, catheter-based radiofrequency- or cryo-energy-based ablation, or one of several surgical techniques, depending on the individual’s comorbidities and associated symptoms.

Stroke in AF occurs primarily as a result of thromboembolism from the left atrium. The lack of atrial contractions in AF leads to blood stasis in the left atrium, and this low flow state increases the risk of thrombosis. The area of the left atrium with the lowest blood flow in AF, and therefore the highest risk of thrombosis, is the left atrial appendage. Multiple clinical trials have demonstrated that anticoagulation reduces the ischemic stroke risk in individuals at moderate- or high-risk of thromboembolic events. Oral anticoagulation in individuals with AF reduces the risk of subsequent stroke and is recommended by the American Heart Association, American College of Cardiology, and the Heart Rhythm Society (2014) joint guidelines on individuals with a history of stroke or transient ischemic attack.⁴



Ambulatory ECG monitoring may play a role in several situations in the detection of AF. In individuals who have undergone ablative treatment for AF, if ongoing AF can be excluded with reasonable certainty, including paroxysmal AF which may not be apparent on ECG during an office visit, anticoagulation therapy could potentially be stopped. In some cases where identifying paroxysmal AF is associated with potential changes in management, longer term monitoring may be considered. There are well-defined management changes that occur in individuals with AF. However, until relatively recently the specific role of long-term (i.e., >48 hours) monitoring in AF was not well-described.

Individuals with cryptogenic stroke are often monitored for the presence of AF because AF is estimated to be the cause of cryptogenic stroke in more than 10% of individuals, and AF increases the risk of stroke.^{5,6} Paroxysmal AF confers an elevated risk of stroke, just as persistent and permanent AF does. In individuals with a high risk of stroke, particularly those with a history of ischemic stroke that is unexplained by other causes, prolonged monitoring to identify paroxysmal AF has been investigated.

Cardiac Rhythm Ambulatory Monitoring Devices

Ambulatory cardiac monitoring with a variety of devices permits the evaluation of cardiac electrical activity over time, in contrast to a static ECG, which only permits the detection of abnormalities in cardiac electrical activity at a single point in time.

A Holter monitor is worn continuously and records cardiac electrical output continuously throughout the recording period. Holter monitors are capable of recording activity for 24 to 72 hours. Traditionally, most Holter monitors have three channels based on three ECG leads. However, some currently available Holter monitors have up to 12 channels. Holter monitors are an accepted intervention in a variety of settings where a short period (24-48 hours) of comprehensive cardiac rhythm assessment is needed (e.g., suspected arrhythmias when symptoms [syncope, palpitations] are occurring daily). These devices are not the focus of this policy.

Various classes of devices are available for situations where longer monitoring than can be obtained with a traditional Holter monitor is needed. Because there may be many devices within each category, a comprehensive description of each is beyond our scope. Devices vary in how data are transmitted to the location where the ECG output is interpreted. Data may be transmitted via cellular phone or landline, or by direct download from the device after its return to the monitoring center. The device classes are described in [Table 1](#).



Table 1. Ambulatory Cardiac Rhythm Monitoring Devices

Device Class	Description	Device Examples
Noncontinuous devices with memory (event recorder)	Devices not worn continuously but rather activated by individual and applied to the skin in the precordial area when symptoms develop	Zio Event Card (iRhythm Technologies) REKA E100 (REKA Health)
Continuous recording devices with longer recording periods	Devices continuously worn and continuously record via ≥ 1 cardiac leads and store data longer than traditional Holter (14 days)	Zio Patch system and ZIO ECG Utilization Service (ZEUS) System (iRhythm Technologies)
External memory loop devices (individual- or autotriggered)	Devices continuously worn and store a single channel of ECG data in a refreshed memory. When the device is activated, the ECG is then recorded from the memory loop for the <i>preceding</i> 30-90 seconds and for the next 60 seconds or so. Devices may be activated by an individual when symptoms occur (individuals-triggered) or by an automated algorithm when changes suggestive of an arrhythmia are detected (autotriggered).	Individual-triggered: Explorer Looping Monitor (LifeWatch Services) Autotriggered: LifeStar AF Express Auto-Detect Looping Monitor (LifeWatch Services) Autotriggered or individual-triggered: King of Hearts Express AF (Card Guard Scientific Survival)
*Implantable memory loop devices (individual- or autotriggered)	Devices similar in design to external memory loop devices but implanted under the skin in the precordial region	Autotriggered or individual-triggered: Reveal XT ICM (Medtronic) and Confirm Rx Insertable Cardiac Monitor (Abbott) Autotriggered: BioMonitor, Biotronik)
*Mobile cardiac outpatient telemetry	Continuously recording or autotriggered memory loop devices that transmit data to a central recording station with real-time monitoring and analysis	CardioNet MCOT (BioTelemetry) LifeStar Mobile Cardiac Telemetry (LifeWatch Services) Zio AT(iRhythm) SmartCardia 7L (SmartCardia)

* The policy criteria is for implantable loop devices and mobile cardiac outpatient telemetry
ECG: electrocardiogram.

There are also devices that combine features of multiple classes. For example, the LifeStar ACT Ex Holter (LifeWatch Services) is a 3-channel Holter monitor but is converted to a mobile cardiac telemetry system if a diagnosis is inconclusive after 24 to 48 hours of monitoring. The BodyGuardian Heart Remote Monitoring System (Boston Scientific Cardiac Diagnostics) is an external autotriggered memory loop device that can be converted to a real-time monitoring system. The eCardio Verité system (eCardio) can switch between an individual-activated event monitor and a continuous telemetry monitor. The Spiderflash-T (LivaNova) is an example of an



external autotriggered or individual-triggered loop recorder, but, like the Zio Patch, can record 2 channels for 14 to 40 days.

Summary of Evidence

Implantable Loop Recording

For individuals who have signs and/or symptoms suggestive of arrhythmia with infrequent symptoms who receive patient- or auto-activated implantable ambulatory event monitoring, the evidence includes RCTs comparing implantable loop recordings (ILRs) with shorter term monitoring, usually 24- to 48-hour Holter monitoring, and many observational studies. Relevant outcomes are overall survival (OS), morbid events, medication use, and treatment-related morbidity. Studies assessing prolonged implantable loop recorders (ILRs) in patients have reported high rates of arrhythmia detection compared with shorter external events or Holter monitoring. These studies have supported use of a progression in diagnostics from an external event monitor to ILR when longer monitoring is needed. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Mobile Cardiac Outpatient Telemetry

This policy addresses whether the addition of real-time mobile cardiac outpatient telemetry (MCOT) to ambulatory cardiac monitoring is associated with improved outcomes. Two factors must be addressed in evaluating MCOT: (1) the inherent detection capability of the monitoring devices and (2) whether the real-time transmission and interpretation of data confers an incremental health benefit. The proposed addition of real-time monitoring suggests that there may be a subset of individuals who require immediate intervention when an arrhythmia is detected. Because it is not clear which individuals comprise that subset, or whether identification of those individuals in the outpatient setting leads to improved outcomes (e.g., reduced risks of sudden cardiac death), the evaluation of the second factor requires studies that directly assess outcomes, not just arrhythmia detection rates.

The purpose of outpatient cardiac telemetry in individuals with signs or symptoms suggestive of arrhythmia is to provide an alternative method of transmitting electrical cardiac activity data to healthcare providers.

One RCT by Rothman et al (2007) compared MCOT with standard event monitors.⁹⁰ This trial involved 305 individuals randomized to the LOOP recorder or to MCOT (CardioNet) and



monitored for up to 30 days. Individuals were recruited from 17 centers. Investigators and individuals were not blinded to randomization assignment. Monitor strips and diagnoses were reviewed by an electrophysiologist blinded to the monitoring device assignment. Most individuals in the LOOP recorder group had an individual-triggered event monitor. Only a subset of individuals (n=50) had autotrigger devices, thus precluding comparison of MCOT and autotrigger devices. Analyses were conducted on individuals completing at least 25 days of monitoring. The primary end point was either confirmation or exclusion of arrhythmic cause of the individual's symptoms. Arrhythmias were classified as either clinically significant or clinically insignificant. The diagnostic endpoint (confirmation or exclusion of arrhythmic cause of symptoms) was significantly different between the 2 groups. The difference in rates was primarily due to detection of asymptomatic (not associated with simultaneous symptoms) arrhythmias in the MCOT group, symptoms consisting of rapid AF and/or flutter (15 individuals vs. one individual), and ventricular tachycardia defined as more than 3 beats and rate greater than 100 (14 individuals vs. two individuals). These differences were thought to be clinically significant rhythm disturbances and the likely causes of the individuals' symptoms. In this trial, median time to diagnosis in the total study population was seven days in the MCOT group and nine days in the LOOP group. The trialists did not comment on the clinical impact (changes in management) of these findings in individuals for whom the rhythm disturbance did not occur simultaneously with symptoms.

Arrhythmia Detection

Derkac et al (2017) retrospectively reviewed the BioTelemetry database of individuals receiving ambulatory ECG monitoring, selecting individuals prescribed MCOT (n=69,977) and individuals prescribed an autotrigger looping event recorder (AT-LER) (n=8513).⁹¹ Individuals were diagnosed with palpitations, syncope and collapse, AF, tachycardia, and/or TIA. Individuals given the MCOT were monitored for an average of 20 days and individuals given the AT-LER were monitored an average of 27 days. The diagnostic yield using MCOT was significantly higher than that using AT-LER for several events: 128% higher for AF, 54% higher for bradycardia, 17% higher for ventricular pause, 80% higher for SVT, and 222% higher for ventricular tachycardia. Mean time to diagnosis for each asymptomatic arrhythmia was shorter for individuals monitored by MCOT than by AT-LER. There was no discussion of management changes or health outcomes based on monitoring results.

Kadish et al (2010) evaluated the frequency with which events transmitted by MCOT represented emergent arrhythmias, thereby indirectly assessing the clinical utility of real-time outpatient monitoring.⁹² Medical records from 26,438 individuals who had undergone MCOT during a 9-month period from a single service provider were retrospectively examined. During a mean



monitoring period of 21 days, 21% (5,459) had an arrhythmic event requiring physician notification. Of these, 1% (260) had an event that could be considered potentially emergent. These potentially emergent events included 120 individuals with wide-complex tachycardia, 100 individuals with sinus pauses 6 seconds or longer, and 42 with sustained bradycardia at less than 30 beats per minute.

A number of uncontrolled case series have reported on arrhythmia detection rates of MCOT.^{93, 94, 95, 96} One study (Joshi et al [2005]) described the outcomes of a consecutive case series of 100 individuals.⁹³ Included individuals had the following symptoms: palpitations (47%), dizziness (24%), or syncope (19%). Individuals being evaluated for the efficacy of drug treatment (25%) were also included. Clinically significant arrhythmias were detected in 51% of the individuals, but half of these individuals were asymptomatic. The authors commented that the automatic detection resulted in an increased diagnostic yield, but there was no discussion of its unique features (i.e., the real-time analysis, transmission, and notification of arrhythmia).

Atrial Fibrillation Detection

In the largest study evaluating the diagnostic yield of MCOT for AF, Favilla et al (2015) evaluated a retrospective cohort of 227 individuals with cryptogenic stroke or TIA who underwent 28 days of monitoring with MCOT.⁹⁷ AF was detected in 14% (31/227) of individuals, of whom 3 reported symptoms at the time of AF. Oral anticoagulation was initiated in 26 (84%) individuals diagnosed with AF. Of the remaining 5 (16%) not on anticoagulation therapy, one had a prior history of gastrointestinal bleeding, three were unwilling to accept the risk of bleeding related to the use of anticoagulants, and one failed to follow up.

Miller et al (2013) retrospectively analyzed paroxysmal AF detection rates among 156 individuals evaluated with MCOT within 6 months of a cryptogenic stroke or TIA.³³ Over a median 21-day period of MCOT monitoring (range, 1-30 days), AF was detected in 17.3% of individuals. Mean time to first occurrence of AF was 9 days (range, 1-21 days).

Tayal et al (2008) retrospectively analyzed individuals with cryptogenic stroke who had not been diagnosed with AF by standard monitoring.⁹⁶ In this study, 13 (23%) of 56 individuals with cryptogenic stroke had AF detected by MCOT. Twenty-seven asymptomatic AF episodes were detected in the 13 individuals, 23 of them were less than 30 seconds in duration. In contrast, Kalani et al (2015) reported a diagnostic yield for AF of 4.7% (95% CI, 1.5% to 11.9%) in a series of 85 individuals with cryptogenic stroke.⁹⁸ In this series, 82.4% of individuals had completed transesophageal echocardiography (TEE), cardiac magnetic resonance imaging (cMRI), or both, with negative results. Three devices were used and described as MCOT devices: 34% received



LifeStar ACT ambulatory cardiac telemetry, 41% received the LifeStar AF Express autodetect looping monitor, and 25% received the Cardiomedix cardiac event monitor. While the authors reported that there was a system in place to transmit the data for review, it is unclear whether data were sent in “real-time.”

Narasimha et al (2018) published results of a study in which 33 individuals wore both an external loop recorder (ELR) and a Kardia monitor to screen for AF during a period of 14 to 30 days.⁹⁹ Individuals were 18 years or older, had palpitations less often than daily but more frequently than several times per month, and prior nondiagnostic ECGs. Exclusion criteria included myocardial infarction within the last three months, history of ventricular tachycardia/fibrillation, unstable angina, and syncope. Study personnel viewed the Kardia monitor recordings once daily and a physician was contacted if a serious or sustained arrhythmia was detected. Individuals were also monitored by the ELR company, which notified a physician on call when necessary. All 33 individuals had a diagnosis using the Kardia monitor and 24 individuals received a diagnosis using the ELR (p=0.001).

Dorr et al (2019) compared the diagnostic accuracy of a smartwatch system with cardiologists' interpretation of an ECG in the diagnostic accuracy to detect AF.¹⁰⁰ The smartwatch system uses an algorithm to enable rhythm analysis of the photoplethysmographic signals. The population consisted of 508 hospitalized individuals who had interpretable ECG and photoplethysmographic recordings. The photoplethysmographic algorithm compared with the cardiologists' diagnoses had a sensitivity of 94% and a specificity of 98%. A limitation of the study was that many of the recordings were excluded due to insufficient signal quality (148 of 672). The investigators concluded that detection of AF is feasible with a smartwatch, though signal quality issues need to be resolved and a broader population needs to be tested.

Post-Transcatheter Aortic Valve Replacement

Beccarino et al (2024) conducted a multicenter study investigating a 30 day MCOT protocol initiative after transcatheter aortic valve replacement (TAVR) to evaluate its utility in detecting conduction disturbances and tachyarrhythmias in 693 patients without preexisting or in hospital cardiac implantable devices.¹⁰¹ The primary outcomes included post discharge permanent pacemaker (PPM) implantation, detection of actionable arrhythmias, and effects on length of hospital stay. 21 patients required PPM placement, 8 of which had no conduction abnormality on initial or discharge ECG. MCOT monitoring detected new AF or flutter in 59 (8.6%) patients. Prior to the MCOT initiative, 1281 patients underwent TAVR over a one-year period. Patients in the MCOT initiative group had a statistically significant shorter length of hospital stay than the pre-initiative group (2.5 ± 4.5 vs. 3.0 ± 3.8 days; p<.001). Limitations included the



nonrandomized design, outcome assessment limited to 30 days, potential missed events due to imperfect monitoring compliance, confounding from evolving TAVR practices and technologies, and potential influences from the COVID 19 era on hospitalization practices.

Nuche et al (2024) conducted a multicenter observational study evaluating continuous ambulatory ECG monitoring to detect subclinical new onset AF after transcatheter aortic valve implantation (TAVI) in 700 patients without prior AF or in hospital arrhythmias.¹⁰² The primary outcomes included the incidence, predictors, and clinical significance of subclinical AF. New-onset AF was identified in 7% of patients, with a median time to first episode of 2 days (interquartile range [IQR]: 1 to 6), a median total AF duration of 185 minutes (IQR: 43 to 421), a longest AF episode of 138 minutes (IQR: 48.9 to 505.6), and an AF burden of 0.7% (IQR: 0.3 to 2.8). In the logistic regression analysis, the baseline mean transaortic gradient was the only independent predictor of new-onset AF, with a statistically significant association in both univariable analysis (OR: 1.04 per mmHg; 95% CI: 1.01 to 1.06; p=.005) and multivariable analysis (OR: 1.04 per mmHg; 95% CI: 1.01 to 1.06; p=.006). Limitations included heterogeneous patient selection across centers, retrospective analysis of prospectively collected data, variable clinical decision-making regarding anticoagulation, disruptions in follow up related to the COVID 19 pandemic, exclusion of pacemaker patients leading to selection bias, and incomplete long term arrhythmia surveillance.

Muntané-Carol et al (2021) conducted a prospective multicenter study investigating 14 day ambulatory electrocardiographic monitoring after minimalist TAVR in 459 consecutive patients without preexisting or in hospital pacemakers.¹⁰³ The primary outcomes included the incidence and timing of delayed high degree atrioventricular block (HAVB) or complete heart block (CHB). Delayed HAVB or CHB occurred in 21 (4.6%) patients at a median of 5 days post procedure (IQR: 4 to 6), leading to pacemaker implantation in 17 (81%) patients. Limitations noted by the authors included the nonrandomized design, lack of a central ECG adjudication system, use of two different monitoring devices, small sample size of self-expanding valve recipients, and insufficient statistical power to identify independent predictors of late conduction disturbances.

Summary: MCOT for Patients with Symptoms of Arrhythmia

The available evidence suggests that MCOT is likely to be at least as good at detecting arrhythmias as ambulatory event monitoring. Compared with ambulatory event monitoring, MCOT is associated with the theoretical advantage of real-time monitoring, permitting for emergent intervention for potentially life-threatening arrhythmias. One study reported that 1% of arrhythmic events detected on MCOT during a mean monitoring period of 21 days per



individual could be considered potentially emergent. However, no randomized studies were identified that addressed whether the use of MCOT is associated with differences in the management of or outcomes after these potentially emergent events; one observational study reported a benefit of MCOT on hospital readmission in patient with prior stroke. The addition of real-time monitoring to outpatient ambulatory monitoring is considered an enhancement to existing technology.

For individuals who have signs and/or symptoms suggestive of arrhythmia who receive outpatient cardiac telemetry, the evidence includes an RCT and nonrandomized studies evaluating rates of arrhythmia detection using outpatient cardiac telemetry. Relevant outcomes are overall survival (OS) and morbid events. The available evidence has suggested that outpatient cardiac telemetry is at least as good at detecting arrhythmias as ambulatory event monitoring. However, studies have not evaluated whether the real-time monitoring feature of outpatient cardiac telemetry leads to reduced cardiac events and mortality. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in [Table 2](#).

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT06519747	Enhanced DETECTION of PeriOperative Atrial Fibrillation After Noncardiac Surgery with Continuous Electrocardiographic Monitoring (DETECT-POAF)	750	Dec 2026
NCT06564012	Wearable Cardiac Monitor to Enhance Detection of Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation (WEAR-HF)	100	Dec 2026



NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT06542770	Subtle Ultrasound Atrial Anomalies Predicts the Early Diagnosis of Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Patients With Cryptogenic Stroke. A Randomized Trial (CRIPTO-FAST)	100	Dec 2024
NCT05957315	Mobile Cardiac Outpatient Telemetry for Unexplained Syncope: Time to Treatment, Arrhythmia Diagnosis and Outcome	160	Oct 2025
NCT04371055	Intensive Heart Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study	5227 (actual)	Dec 2026
NCT03940066	Evaluation of Ambulatory Monitoring of Patients After High-risk Acute Coronary Syndrome Using Two Different Systems: Biomonitor-2 and Kardia Mobile	169 (actual)	Jun 2024 (actual)
Unpublished			
NCT02786940	Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients after Discharge (REMOSYNC)	99	Apr 2020
NCT03541616	Prevalence of Subclinical Atrial Fibrillation in High Risk Heart Failure Patients and Its Temporal Relationship With Hospital Readmission for Heart Failure (PROTECT-HF)	242	Mar 2023

NCT: national clinical trial.

Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.



2025 Input

Clinical input was sought to help determine whether the use of mobile cardiac outpatient telemetry for individuals with signs and/or symptoms suggestive of arrhythmia would provide a clinically meaningful improvement in net health outcome and represents generally accepted medical practice in selected patients. In response to requests, clinical input was received from 3 respondents, including 2 specialty society-level responses and 1 clinical health system response.

For individuals who experience infrequent symptoms (less frequently than every 48 hours) suggestive of cardiac arrhythmias (i.e., severe palpitations, dizziness, or clinically significant presyncope or syncope) who receive outpatient cardiac telemetry, clinical input supports this use provides a clinically meaningful improvement in net health outcomes and indicates this use is consistent with generally accepted medical practice in a subgroup of appropriately selected individuals when any of the conditions below are met:

- Evaluation of recurrent unexplained clinically significant presyncope, syncope, severe palpitations or dizziness when:
 - Symptoms are thought to be due to a cardiac arrhythmia as the most likely diagnosis; and
 - Holter monitor and/or external AEM has been nondiagnostic or contraindicated; and
 - There is documentation that real-time monitoring is essential for patient safety and will lead to immediate clinical changes such as medication or other emergent procedures;

OR

- Evaluation of cryptogenic stroke thought to be caused by atrial fibrillation, with non-diagnostic 24- to 48-hour Holter monitor or 48-hour telemetry.

2014 Input

In response to requests, input was received from three physician specialty societies and four academic medical centers (three reviews) while this policy was under review in 2014. Input was obtained to provide information on mobile cardiac outpatient telemetry and new devices. There was no consensus whether mobile cardiac outpatient telemetry is medically necessary. While reviewers agreed that mobile cardiac outpatient telemetry is comparable to event monitors for arrhythmia detection, they did not agree on whether the real-time monitoring provides incremental benefit over external event monitors or is associated with improved health outcomes compared with external event monitors. There was consensus on the medical necessity of externally worn event monitors with longer continuous recording periods as an alternative to Holter monitors or event monitors. For implantable memory loop devices that are



smaller than older-generation devices, there was consensus that these devices improve the likelihood of obtaining clinically useful information due to improved ease of use, but there was no consensus that such devices improve clinical outcomes and are medically necessary.

2009 Input

In response to requests, input was received from one physician specialty society and four academic medical centers (5 reviews) while this policy was under review in 2009. There were differences among reviewers on outpatient cardiac telemetry, with some reviewers concluding it had a role in certain subsets of patients (e.g., in those with sporadic atrial fibrillation [AF]). Other reviewers commented that the value of this technology should be considered in both providing a diagnosis and in making treatment decisions. At times, excluding arrhythmia as a cause of a patient's symptoms is an important finding.

Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the policy conclusions.

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Neurology

In 2014 (reaffirmed 2022), the American Academy of Neurology updated its guidelines on the prevention of stroke in individuals with nonvalvular AF (NVAF).¹⁰⁵ These guidelines made the following recommendations on the identification of individuals with occult NVAF.

- "Clinicians might obtain outpatient cardiac rhythm studies in individuals with cryptogenic stroke without known NVAF, to identify individuals with occult NVAF (Level C).
- Clinicians might obtain cardiac rhythm studies for prolonged periods (e.g., for 1 or more weeks) instead of shorter periods (e.g., 24 hours) in individuals with cryptogenic stroke



without known NVAf, to increase the yield of identification of individuals with occult NVAf (Level C)."

American Heart Association, American College of Cardiology, et al

The American College of Cardiology (ACC), the American Heart Association (AHA), the American College of Clinical Pharmacy (ACCP), and the Heart Rhythm Society (HRS) (2023) updated guidelines initially issued in 2014⁴ on the management of individuals with atrial fibrillation (AF).¹⁰⁶ These guidelines recommended the use of Holter or event monitoring if the diagnosis of the type of arrhythmia is in question, or as a means of evaluating rate control. [Table 3](#) summarizes guideline-recommended monitoring.

The ACC/AHA/HRS (2017) collaborated on guidelines on the evaluation and management of individuals with syncope¹⁰⁷, and individuals with ventricular arrhythmias¹⁰⁸. Cardiac monitoring recommendations are summarized below in [Tables 3 and 4](#).

Table 3. Cardiac Monitoring Recommendations, AHA/ACC/HRS

Recommendation	COR ^a	LOE ^b
Choice of a specific cardiac monitor should be determined on the basis of frequency and nature of syncope events. ¹⁰⁷	I	C-EO
To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, the following external cardiac monitoring approaches can be useful: Holter monitor, transtelephonic monitor, external loop recorder, patch recorder, and mobile cardiac outpatient telemetry. ¹⁰⁷	Ila	B-NR
To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, an implantable cardiac monitor can be useful. ¹⁰⁷	Ila	B-R
Ambulatory electrocardiographic monitoring is useful to evaluate whether symptoms including palpitations, presyncope, or syncope, are caused by ventricular arrhythmia ¹⁰⁸	I	B-NR
In patients with stroke or TIA of undetermined cause, initial cardiac monitoring and, if needed, extended monitoring with an implantable loop recorder are reasonable to improve detection of AF. ¹⁰⁶	Ila	B-R

ACC: American College of Cardiology; AF: atrial fibrillation; AHA: American Heart Association; COR: class of recommendation; HRS: Heart Rhythm Society; LOE: level of evidence; TIA: transient ischemic attack.

^a COR definitions: I: strong recommendation; Ila or 2a: benefit probably exceeds risk (moderate).

^b LOE definitions: B-NR: moderate level based on well-executed nonrandomized studies; B-R: moderate level based on randomized trials; C-EO: consensus of expert opinion based on clinical experience.



Table 4. Patient Selection Recommendations by Cardiac Rhythm Monitor, AHA/ACC/HRS

Type of Monitor	Patient Selection
Holter monitor	<ul style="list-style-type: none"> • Symptoms frequent enough to be detected within 24 to 72 hours
Patient-activated event monitor	<ul style="list-style-type: none"> • Frequent spontaneous symptoms likely within 2 to 6 weeks • Limited use when syncope associated with sudden incapacitation
External loop recorder (patient or auto-triggered)	<ul style="list-style-type: none"> • Frequent spontaneous symptoms likely to occur within 2 to 6 weeks
External patch recorder	<ul style="list-style-type: none"> • Alternative to external loop recorder • Leadless, so more comfortable, resulting in improved compliance • Offers only 1-lead recording
Mobile cardiac outpatient telemetry	<ul style="list-style-type: none"> • Spontaneous symptoms related to syncope and rhythm correlation • High-risk patients needing real-time monitoring
Implantable cardiac monitor	<ul style="list-style-type: none"> • Recurrent, infrequent, unexplained syncope

ACC: American College of Cardiology; AHA: American Heart Association; HRS: Heart Rhythm Society.

International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society

The International Society for Holter and Noninvasive Electrocardiology and the Heart Rhythm Society (HRS; 2017) issued a consensus statement on ambulatory electrocardiogram and external monitoring and telemetry.¹⁰⁹ Below are two summary tables from the consensus statement, detailing advantages and limitations of ambulatory electrocardiogram techniques (see [Table 5](#)) and recommendations for the devices that are relevant to this policy (see [Table 6](#)).

Table 5. Advantages and Limitations of Ambulatory Electrocardiogram Techniques, International Society for Holter and Noninvasive Electrocardiology/HRS



ECG Monitoring Technique	Advantages	Limitations
Holter monitoring	<ul style="list-style-type: none"> Records and documents continuous 3- to 32-lead ECG signal simultaneously with biologic signals during normal daily activities Physicians familiar with analysis software and scanning services 	<ul style="list-style-type: none"> Frequent noncompliance with symptom logs and event markers Frequent electrode detachments Signal quality issues due to skin adherence, tangled wires, dermatitis Absence of real-time data analysis Poor patient acceptance of electrodes
Patch ECG monitors	<ul style="list-style-type: none"> Long-term recording of ≥ 14 days Excellent patient acceptance 	<ul style="list-style-type: none"> Limited ECG from closely spaced electrodes, lacking localization of arrhythmia origin Inconsistent ECG quality due to body type variations
External loop recorders	<ul style="list-style-type: none"> Records only selected ECG segments marked as events either automatically or manually by patient Immediate alarm generation on event detection 	<ul style="list-style-type: none"> Single-lead ECG, lacking localization of arrhythmia origin Cannot continuously document cardiac rhythm Requires patient to wear electrodes continuously
Event recorders	<ul style="list-style-type: none"> Records only selected ECG segments after an event is detected by patient Immediate alarm generation at event detected by patient Well-tolerated by patient 	<ul style="list-style-type: none"> Single-lead ECG, lacking localization of arrhythmia origin Cannot continuously document cardiac rhythm Diagnostic yield dependent on patient ability to recognize correct symptom
Mobile cardiac telemetry	<ul style="list-style-type: none"> Multilead, so higher sensitivity and specificity of arrhythmia detection Streams data continuously; can be programmed to autodetect and autosend events at prescribed time intervals Immediate alarm generation on event without patient interaction 	<ul style="list-style-type: none"> Long-term patient acceptance is reduced due to requirement of daily electrode changes

ECG: electrocardiogram; HRS: Heart Rhythm Society.



Table 6. Select Recommendations for Ambulatory Electrocardiogram and External Monitoring or Telemetry, International Society for Holter and Noninvasive Electrocardiology/HRS

Recommendation	COR^a	LOE^b
Selection of ambulatory ECG		
Holter monitoring when symptomatic events anticipated within 48 hours	I	B-NR
Extended ambulatory ECG (15 to 30 days) when symptomatic events are not daily or are uncertain	I	B-R
Continuous monitoring (1 to 14 days) to quantify arrhythmia burden and patterns	I	B-NR
Specific conditions for use of ambulatory ECG		
Unexplained syncope when tachycardia suspected	I	B-R
Unexplained palpitation	I	B-R
Detection of atrial fibrillation, triggering arrhythmias, and postconversion pauses	Ila	B-NR
Cryptogenic stroke, to detect undiagnosed atrial fibrillation	I	B-R

COR: class of recommendation; ECG: electrocardiogram; HRS: Heart Rhythm Society; LOE: level of evidence.

^a COR definitions: I: strong recommendation; Ila: benefit probably exceeds risk.

^b LOE definitions: B-NR: moderate level based on well-executed nonrandomized studies; B-R: moderate level based on randomized trials.

US Preventive Services Task Force Recommendations

In 2022, the US Preventive Services Task Force updated its recommendation on Screening for Atrial Fibrillation and concluded, "For adults 50 years or older who do not have signs or symptoms of atrial fibrillation. The current evidence is insufficient to assess the balance of benefits and harms of screening for AF (Grade: I statement)."¹¹⁰

Medicare National Coverage

The Centers for Medicare & Medicaid Services (2004) implemented a national coverage determination for electrocardiographic services.¹¹¹ This national coverage determination includes descriptions of the Holter monitor and event recorders (both external loop recorders and implantable loop recorders). Ambulatory cardiac monitors are covered when there is documentation of medical necessity. Indications for use include detection of symptomatic



transient arrhythmias and determination of arrhythmic drug therapy (to either initiate, revise, or discontinue the therapy).

Regulatory Status

Some of the newer devices are described in the Background section for informational purposes. Because there may be many devices within each category, a comprehensive description of individual devices is beyond the scope of this policy. US Food and Drug Administration product codes include: DSH, DXH, DQK, DSI, MXD, MHX.

References

1. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). *Eur Heart J*. Nov 2009; 30(21): 2631-71. PMID 19713422
2. National Institute for Health and Care Excellence (NICE). Transient loss of consciousness ('blackouts') in over 16s [CG109]. 2023; <https://www.nice.org.uk/guidance/cg109>. Accessed March 12, 2026.
3. Raviele A, Giada F, Bergfeldt L, et al. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. *Europace*. Jul 2011; 13(7): 920-34. PMID 21697315
4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. Dec 02 2014; 130(23): 2071-104. PMID 24682348
5. Mittal S, Movsowitz C, Steinberg JS. Ambulatory external electrocardiographic monitoring: focus on atrial fibrillation. *J Am Coll Cardiol*. Oct 18 2011; 58(17): 1741-9. PMID 21996384
6. Christensen LM, Krieger DW, Højberg S, et al. Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. *Eur J Neurol*. Jun 2014; 21(6): 884-9. PMID 24628954
7. Hoefman E, Bindels PJ, van Weert HC. Efficacy of diagnostic tools for detecting cardiac arrhythmias: systematic literature search. *Neth Heart J*. Nov 2010; 18(11): 543-51. PMID 21113379
8. Farris GR, Smith BG, Oates ET, et al. New atrial fibrillation diagnosed by 30-day rhythm monitoring. *Am Heart J*. Mar 2019; 209: 29-35. PMID 30639611
9. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. *Am J Cardiol*. Aug 15 2013; 112(4): 520-4. PMID 23672988
10. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. *Am J Med*. Jan 2014; 127(1): 95.e11-7. PMID 24384108
11. Solomon MD, Yang J, Sung SH, et al. Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring. *BMC Cardiovasc Disord*. Feb 17 2016; 16: 35. PMID 26883019
12. Wineinger NE, Barrett PM, Zhang Y, et al. Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals. *Heart Rhythm*. Jan 2019; 16(1): 26-30. PMID 30118885



13. Go AS, Reynolds K, Yang J, et al. Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study. *JAMA Cardiol.* Jul 01 2018; 3(7): 601-608. PMID 29799942
14. Bolourchi M, Batra AS. Diagnostic yield of patch ambulatory electrocardiogram monitoring in children (from a national registry). *Am J Cardiol.* Mar 01 2015; 115(5): 630-4. PMID 25591894
15. Eisenberg EE, Carlson SK, Doshi RH, et al. Chronic ambulatory monitoring: results of a large single-center experience. *J Innovations Cardiac Rhythm Manage.* Nov 2014;5:1818-1823.
16. Schreiber D, Sattar A, Drigalla D, et al. Ambulatory cardiac monitoring for discharged emergency department patients with possible cardiac arrhythmias. *West J Emerg Med.* Mar 2014; 15(2): 194-8. PMID 24672611
17. Mullis AH, Ayoub K, Shah J, et al. Fluctuations in premature ventricular contraction burden can affect medical assessment and management. *Heart Rhythm.* Oct 2019; 16(10): 1570-1574. PMID 31004780
18. Reed MJ, Grubb NR, Lang CC, et al. Diagnostic yield of an ambulatory patch monitor in patients with unexplained syncope after initial evaluation in the emergency department: the PATCH-ED study. *Emerg Med J.* Aug 2018; 35(8): 477-485. PMID 29921622
19. Eysenck W, Freemantle N, Sulke N. A randomized trial evaluating the accuracy of AF detection by four external ambulatory ECG monitors compared to permanent pacemaker AF detection. *J Interv Card Electrophysiol.* Apr 2020; 57(3): 361-369. PMID 30741360
20. Kabali C, Xie X, Higgins C. Long-Term Continuous Ambulatory ECG Monitors and External Cardiac Loop Recorders for Cardiac Arrhythmia: A Health Technology Assessment. *Ont Health Technol Assess Ser.* 2017; 17(1): 1-56. PMID 28194254
21. Balmelli N, Naegeli B, Bertel O. Diagnostic yield of automatic and patient-triggered ambulatory cardiac event recording in the evaluation of patients with palpitations, dizziness, or syncope. *Clin Cardiol.* Apr 2003; 26(4): 173-6. PMID 12708623
22. Ermis C, Zhu AX, Pham S, et al. Comparison of automatic and patient-activated arrhythmia recordings by implantable loop recorders in the evaluation of syncope. *Am J Cardiol.* Oct 01 2003; 92(7): 815-9. PMID 14516882
23. Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. *Am J Cardiol.* May 01 2005; 95(9): 1055-9. PMID 15842970
24. Dagres N, Kottkamp H, Piorkowski C, et al. :Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: implications for patient follow-up. *Int J Cardiol.* Mar 18 2010; 139(3): 305-6. PMID 18990460
25. Pokushalov E, Romanov A, Corbucci G, et al. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. *J Cardiovasc Electrophysiol.* Apr 2011; 22(4): 369-75. PMID 20958836
26. Chao TF, Lin YJ, Tsao HM, et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. *J Am Coll Cardiol.* Nov 29 2011; 58(23): 2380-5. PMID 22115643
27. Kapa S, Epstein AE, Callans DJ, et al. Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study. *J Cardiovasc Electrophysiol.* Aug 2013; 24(8): 875-81. PMID 23577826
28. Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. *JAMA Intern Med.* Jan 28 2013; 173(2): 149-56. PMID 23266597
29. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. *J Am Coll Cardiol.* Feb 23 2010; 55(8): 735-43. PMID 20170810
30. Gumbinger C, Krumsdorf U, Veltkamp R, et al. Continuous monitoring versus HOLTER ECG for detection of atrial fibrillation in patients with stroke. *Eur J Neurol.* Feb 2012; 19(2): 253-7. PMID 21895885
31. Lazzaro MA, Krishnan K, Prabhakaran S. Detection of atrial fibrillation with concurrent holter monitoring and continuous cardiac telemetry following ischemic stroke and transient ischemic attack. *J Stroke Cerebrovasc Dis.* Feb 2012; 21(2): 89-93. PMID 20656504



32. Cotter PE, Martin PJ, Ring L, et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. *Neurology*. Apr 23 2013; 80(17): 1546-50. PMID 23535493
33. Miller DJ, Khan MA, Schultz LR, et al. Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. *J Neurol Sci*. Jan 15 2013; 324(1-2): 57-61. PMID 23102659
34. Ho JS, Ho ES, Yeo LL, et al. Use of wearable technology in cardiac monitoring after cryptogenic stroke or embolic stroke of undetermined source: a systematic review. *Singapore Med J*. Jul 01 2024; 65(7): 370-379. PMID 38449074
35. Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol*. Apr 2015; 14(4): 377-87. PMID 25748102
36. Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Stroke*. Feb 2014; 45(2): 520-6. PMID 24385275
37. Kamel H, Navi BB, Elijovich L, et al. Pilot randomized trial of outpatient cardiac monitoring after cryptogenic stroke. *Stroke*. Feb 2013; 44(2): 528-30. PMID 23192756
38. Higgins P, MacFarlane PW, Dawson J, et al. Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. *Stroke*. Sep 2013; 44(9): 2525-31. PMID 23899913
39. Sinha AM, Diener HC, Morillo CA, et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. *Am Heart J*. Jul 2010; 160(1): 36-41.e1. PMID 20598970
40. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med*. Jun 26 2014; 370(26): 2478-86. PMID 24963567
41. Brachmann J, Morillo CA, Sanna T, et al. Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. *Circ Arrhythm Electrophysiol*. Jan 2016; 9(1): e003333. PMID 26763225
42. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med*. Jun 26 2014; 370(26): 2467-77. PMID 24963566
43. Kaura A, Sztriha L, Chan FK, et al. Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial. *Eur J Med Res*. Jul 26 2019; 24(1): 25. PMID 31349792
44. Ritter MA, Kochhäuser S, Duning T, et al. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. *Stroke*. May 2013; 44(5): 1449-52. PMID 23449264
45. Etgen T, Hochreiter M, Mundel M, et al. Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report. *Stroke*. Jul 2013; 44(7): 2007-9. PMID 23674523
46. Tung CE, Su D, Turakhia MP, et al. Diagnostic Yield of Extended Cardiac Patch Monitoring in Patients with Stroke or TIA. *Front Neurol*. 2014; 5: 266. PMID 25628595
47. Rosenberg MA, Samuel M, Thosani A, et al. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. *Pacing Clin Electrophysiol*. Mar 2013; 36(3): 328-33. PMID 23240827
48. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. *J Interv Card Electrophysiol*. Jun 2000; 4(2): 369-82. PMID 10936003
49. Israel CW, Grönfeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. *J Am Coll Cardiol*. Jan 07 2004; 43(1): 47-52. PMID 14715182
50. Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. *Circulation*. Jan 1994; 89(1): 224-7. PMID 8281651
51. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol*. Jan 2000; 35(1): 183-7. PMID 10636278



52. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. *J Am Coll Cardiol.* Nov 27 2007; 50(22): 2156-61. PMID 18036454
53. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. *Eur Heart J.* May 21 2016; 37(20): 1591-602. PMID 26888184
54. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. *BMJ.* Aug 25 2007; 335(7616): 383. PMID 17673732
55. Langén V, Winstén AK, Airaksinen KEJ, et al. Clinical outcomes of atrial fibrillation screening: a meta-analysis of randomized controlled trials. *Ann Med.* Dec 2025; 57(1): 2457522. PMID 39862317
56. Benito L, Coll-Vinent B, Gómez E, et al. EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. *Europace.* Nov 2015; 17(11): 1688-93. PMID 26071233
57. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. *Circulation.* Nov 07 2017; 136(19): 1784-1794. PMID 28851729
58. Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial. *JAMA Cardiol.* May 01 2021; 6(5): 558-567. PMID 33625468
59. Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. *Lancet.* Oct 23 2021; 398(10310): 1507-1516. PMID 34469766
60. Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. *Lancet.* Oct 23 2021; 398(10310): 1498-1506. PMID 34469764
61. Lopes RD, Atlas SJ, Go AS, et al. Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. *J Am Coll Cardiol.* Nov 19 2024; 84(21): 2073-2084. PMID 39230544
62. Kemp Gudmundsdottir K, Svennberg E, Friberg L, et al. Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II. *Circulation.* Dec 03 2024; 150(23): 1837-1846. PMID 39217615
63. Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. *JAMA.* Jul 10 2018; 320(2): 146-155. PMID 29998336
64. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol.* May 2015; 38(5): 285-92. PMID 25873476
65. Heckbert SR, Austin TR, Jensen PN, et al. Yield and consistency of arrhythmia detection with patch electrocardiographic monitoring: The Multi-Ethnic Study of Atherosclerosis. *J Electrocardiol.* 2018; 51(6): 997-1002. PMID 30497763
66. Steinhubl SR, Waalen J, Sanyal A, et al. Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening-mHealth Screening to Prevent Strokes (mSToPS). *PLoS One.* 2021; 16(10): e0258276. PMID 34610049
67. Murphy R, Waters R, Murphy A, et al. Risk-based screening for the evaluation of atrial fibrillation in general practice (R-BEAT): a randomized cross-over trial. *QJM.* Mar 01 2025; 118(3): 166-173. PMID 39786890
68. Diederichsen SZ, Frederiksen KS, Xing LY, et al. Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke: A Post Hoc Analysis of the LOOP Randomized Clinical Trial. *JAMA Neurol.* Oct 01 2022; 79(10): 997-1004. PMID 36036546
69. Diederichsen SZ, Xing LY, Frodi DM, et al. Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care: Post Hoc Analysis of the LOOP Randomized Clinical Trial. *JAMA Cardiol.* Apr 01 2023; 8(4): 326-334. PMID 36790817
70. Solbiati M, Casazza G, Dipaola F, et al. The diagnostic yield of implantable loop recorders in unexplained syncope: A systematic review and meta-analysis. *Int J Cardiol.* Mar 15 2017; 231: 170-176. PMID 28052814



71. Burkowitz J, Merzenich C, Grassme K, et al. Insertable cardiac monitors in the diagnosis of syncope and the detection of atrial fibrillation: A systematic review and meta-analysis. *Eur J Prev Cardiol.* Aug 2016; 23(12): 1261-72. PMID 26864396
72. Da Costa A, Defaye P, Romeyer-Bouchard C, et al. Clinical impact of the implantable loop recorder in patients with isolated syncope, bundle branch block and negative workup: a randomized multicentre prospective study. *Arch Cardiovasc Dis.* Mar 2013; 106(3): 146-54. PMID 23582676
73. Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. *Eur Heart J.* Jul 2004; 25(14): 1257-63. PMID 15246645
74. Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. *Circulation.* Jul 03 2001; 104(1): 46-51. PMID 11435336
75. Afzal MR, Gunda S, Waheed S, et al. Role of Outpatient Cardiac Rhythm Monitoring in Cryptogenic Stroke: A Systematic Review and Meta-Analysis. *Pacing Clin Electrophysiol.* Oct 2015; 38(10): 1236-45. PMID 26172621
76. Podoleanu C, DaCosta A, Defaye P, et al. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of the French healthcare system (FRESH study). *Arch Cardiovasc Dis.* Oct 2014; 107(10): 546-52. PMID 25241220
77. Giada F, Gulizia M, Francese M, et al. Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus conventional diagnostic strategy. *J Am Coll Cardiol.* May 15 2007; 49(19): 1951-6. PMID 17498580
78. Ciconte G, Saviano M, Giannelli L, et al. Atrial fibrillation detection using a novel three-vector cardiac implantable monitor: the atrial fibrillation detect study. *Europace.* Jul 01 2017; 19(7): 1101-1108. PMID 27702865
79. Nölker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. *J Cardiovasc Electrophysiol.* Dec 2016; 27(12): 1403-1410. PMID 27565119
80. Sanders P, Pürerfellner H, Pokushalov E, et al. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. *Heart Rhythm.* Jul 2016; 13(7): 1425-30. PMID 26961298
81. Hanke T, Charitos EI, Stierle U, et al. Twenty-four-hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device. *Circulation.* Sep 15 2009; 120(11 Suppl): S177-84. PMID 19752365
82. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. *Circ Arrhythm Electrophysiol.* Apr 2010; 3(2): 141-7. PMID 20160169
83. Ziegler PD, Rogers JD, Ferreira SW, et al. Real-World Experience with Insertable Cardiac Monitors to Find Atrial Fibrillation in Cryptogenic Stroke. *Cerebrovasc Dis.* 2015; 40(3-4): 175-81. PMID 26314298
84. Edvardsson N, Garutti C, Rieger G, et al. Unexplained syncope: implications of age and gender on patient characteristics and evaluation, the diagnostic yield of an implantable loop recorder, and the subsequent treatment. *Clin Cardiol.* Oct 2014; 37(10): 618-25. PMID 24890550
85. Bhangu J, McMahon CG, Hall P, et al. Long-term cardiac monitoring in older adults with unexplained falls and syncope. *Heart.* May 2016; 102(9): 681-6. PMID 26822427
86. Maines M, Zorzi A, Tomasi G, et al. Clinical impact, safety, and accuracy of the remotely monitored implantable loop recorder Medtronic Reveal LINQTM. *Europace.* Jun 01 2018; 20(6): 1050-1057. PMID 29016753
87. Magnusson PM, Olszowka M, Wallhagen M, et al. Outcome of implantable loop recorder evaluation. *Cardiol J.* 2018; 25(3): 363-370. PMID 28840588
88. Katapadi A, Chelikam N, Garg J, et al. Dynamic data-driven management of atrial fibrillation with implantable cardiac monitors: The MONITOR AF study. *Heart Rhythm.* Dec 2025; 22(12): 3050-3056. PMID 39826639
89. Mittal S, Sanders P, Pokushalov E, et al. Safety Profile of a Miniaturized Insertable Cardiac Monitor: Results from Two Prospective Trials. *Pacing Clin Electrophysiol.* Dec 2015; 38(12): 1464-9. PMID 26412309



90. Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. *J Cardiovasc Electrophysiol*. Mar 2007; 18(3): 241-7. PMID 17318994
91. Derkac WM, Finkelmeier JR, Horgan DJ, et al. Diagnostic yield of asymptomatic arrhythmias detected by mobile cardiac outpatient telemetry and autotrigger looping event cardiac monitors. *J Cardiovasc Electrophysiol*. Dec 2017; 28(12): 1475-1478. PMID 28940881
92. Kadish AH, Reiffel JA, Clauser J, et al. Frequency of serious arrhythmias detected with ambulatory cardiac telemetry. *Am J Cardiol*. May 01 2010; 105(9): 1313-6. PMID 20403485
93. Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. *Am J Cardiol*. Apr 01 2005; 95(7): 878-81. PMID 15781022
94. Olson JA, Fouts AM, Padanilam BJ, et al. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. *J Cardiovasc Electrophysiol*. May 2007; 18(5): 473-7. PMID 17343724
95. Saarel EV, Doratotaj S, Sterba R. Initial experience with novel mobile cardiac outpatient telemetry for children and adolescents with suspected arrhythmia. *Congenit Heart Dis*. 2008; 3(1): 33-8. PMID 18373747
96. Tayal AH, Tian M, Kelly KM, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. *Neurology*. Nov 18 2008; 71(21): 1696-701. PMID 18815386
97. Favilla CG, Ingala E, Jara J, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. *Stroke*. May 2015; 46(5): 1210-5. PMID 25851771
98. Kalani R, Bernstein R, Passman R, et al. Low Yield of Mobile Cardiac Outpatient Telemetry after Cryptogenic Stroke in Patients with Extensive Cardiac Imaging. *J Stroke Cerebrovasc Dis*. Sep 2015; 24(9): 2069-73. PMID 26139455
99. Narasimha D, Hanna N, Beck H, et al. Validation of a smartphone-based event recorder for arrhythmia detection. *Pacing Clin Electrophysiol*. May 2018; 41(5): 487-494. PMID 29493801
100. Dörr M, Nohturfft V, Brasier N, et al. The WATCH AF Trial: SmartWATCHes for Detection of Atrial Fibrillation. *JACC Clin Electrophysiol*. Feb 2019; 5(2): 199-208. PMID 30784691
101. Beccarino N, Epstein LM, Khodak A, et al. The utility and impact of outpatient telemetry monitoring in post-transcatheter aortic valve replacement patients. *Cardiovasc Revasc Med*. Jul 2024; 64: 15-20. PMID 38388248
102. Nuche J, Soliman F, Chavarría J, et al. New-onset atrial fibrillation detected by ambulatory ECG monitoring after transcatheter aortic valve implantation. *EuroIntervention*. May 10 2024; 20(9): 591-601. PMID 38726722
103. Muntané-Carol G, Okoh AK, Chen C, et al. Ambulatory Electrocardiographic Monitoring Following Minimalist Transcatheter Aortic Valve Replacement. *JACC Cardiovasc Interv*. Dec 27 2021; 14(24): 2711-2722. PMID 34949396
104. Norlock V, Vazquez R, Dunn A, et al. Comparing the outcomes and costs of cardiac monitoring with implantable loop recorders and mobile cardiac outpatient telemetry following stroke using real-world evidence. *J Comp Eff Res*. Jun 2024; 13(6): e240008. PMID 38602503
105. Culebras A, Messé SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. Feb 25 2014; 82(8): 716-24. PMID 24566225
106. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Jan 02 2024; 83(1): 109-279. PMID 38043043
107. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Aug 01 2017; 70(5): 620-663. PMID 28286222



108. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. Oct 2018; 15(10): e190-e252. PMID 29097320
109. Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. Jul 2017; 14(7): e55-e96. PMID 28495301
110. Davidson KW, Barry MJ, Mangione CM, et al. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. Jan 25 2022; 327(4): 360-367. PMID 35076659
111. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Electrocardiographic Services (20.15). 2004; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?MCDId=16&ExpandComments=n&McdName=Thomson+Micromedex+DrugDex+%C2%AE+C+ompendium+Revision+Request+-+CAG-00391&NCDId=179>. Accessed March 12, 2026.

History

Date	Comments
08/09/16	New policy, add to Cardiology section. Use of MCOT is considered investigational. Policy will be effective 01/01/17.
10/25/16	Effective date revision. Policy will be effective 03/01/17.
02/24/17	Effective date revision. Policy will be effective 03/15/17.
03/15/17	Effective date revision. Policy will be effective 03/17/17.
03/17/17	Effective date revision. Policy will be effective 03/31/17.
03/23/17	Effective date revision. Policy will be effective 03/24/17. Coding update; removed CPT codes 0295T-0298T. Minor formatting update.
08/01/17	Annual Review, approved July 11, 2017. No changes to policy statement.
08/01/18	Annual Review, approved July 13, 2018. Policy updated with literature review through March 2018; references 9, 16 and 17 added. Policy statement unchanged.
08/01/19	Annual Review, approved July 25, 2019. Policy updated with literature review through March 2019, several references added. Policy statements unchanged.
08/01/20	Annual Review, approved July 2, 2020. Policy updated with literature review through May 2020; references added. Policy statements unchanged.
08/01/21	Annual Review, approved July 9, 2021. Policy updated with literature review through March 25, 2021; reference added. Policy statements unchanged.
06/01/22	Interim Review, approved May 9, 2022. Minor edits made for greater clarity. Policy intent unchanged.
08/01/22	Annual Review, approved July 11, 2022. Policy updated with literature review through April 8, 2022; references added. Policy statement unchanged except for a minor edit.



Date	Comments
08/01/23	Annual Review, approved July 10, 2023. Policy updated with literature review through April 11, 2023; references added. Policy statements unchanged. Changed the wording from "patient" to "individual" throughout the policy for standardization where applicable.
02/01/24	Interim Review, approved January 9, 2024. Added policy criteria for which MCOT is now considered medically necessary rather than investigational.
08/01/24	Annual Review, approved July 8, 2024. Policy updated with literature review through April 9, 2024; reference added. Policy statements unchanged.
01/01/26	Annual Review, approved December 23, 2025. The following policy changes are effective April 8, 2026, following 90-day provider notification. Policy updated with literature review through August 29, 2025; references added. Title changed to Mobile Cardiac Telemetry and Implantable Loop Recorders. Added implantable loop recorders as medically necessary when criteria are met. Added CPT code 33285, and HCPCS codes C1764, E0616. Added SOS ASC for implantable loop recorders. Added 11.01.525 Site of Service Ambulatory Service Center (ASC): Select Surgical Procedures in Adults to Related Policies section.
05/01/26	Annual Review, approved April 14, 2026. Policy updated with literature review through December 2, 2025; references added. Removed the term ambulatory event monitor (AEM) for clarity. Minor edits to clarify site of service review is only for implantable loop recorders (ILR) and policy statement updated with minor edits to ILR criteria for greater clarity. All other policy statements unchanged. The following changes are effective August 7, 2026, following 90-day provider notification. Additional policy criterion added for ILR to require a prior non-diagnostic or inconclusive ambulatory cardiac monitoring of at least 14 continuous days. Expanded not medically necessary policy statement to include ILRs and monitoring of asymptomatic individuals.
06/01/26	Minor update. Added header to indicate that site of service review does not apply to Indian Health Services (IHS) facilities.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2026 Premera All Rights Reserved.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.



